Literature DB >> 15635002

Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.

Sarah Palmer1, Mary Kearney, Frank Maldarelli, Elias K Halvas, Christian J Bixby, Holly Bazmi, Diane Rock, Judith Falloon, Richard T Davey, Robin L Dewar, Julia A Metcalf, Scott Hammer, John W Mellors, John M Coffin.   

Abstract

To investigate the extent to which drug resistance mutations are missed by standard genotyping methods, we analyzed the same plasma samples from 26 patients with suspected multidrug-resistant human immunodeficiency virus type 1 by using a newly developed single-genome sequencing technique and compared it to standard genotype analysis. Plasma samples were obtained from patients with prior exposure to at least two antiretroviral drug classes and who were on a failing antiretroviral regimen. Standard genotypes were obtained by reverse transcriptase (RT)-PCR and sequencing of the bulk PCR product. For single-genome sequencing, cDNA derived from plasma RNA was serially diluted to 1 copy per reaction, and a region encompassing p6, protease, and a portion of RT was amplified and sequenced. Sequences from 15 to 46 single viral genomes were obtained from each plasma sample. Drug resistance mutations identified by single-genome sequencing were not detected by standard genotype analysis in 24 of the 26 patients studied. Mutations present in less than 10% of single genomes were almost never detected in standard genotypes (1 of 86). Similarly, mutations present in 10 to 35% of single genomes were detected only 25% of the time in standard genotypes. For example, in one patient, 10 mutations identified by single-genome sequencing and conferring resistance to protease inhibitors (PIs), nucleoside analog reverse transcriptase inhibitors, and nonnucleoside reverse transcriptase inhibitors (NNRTIs) were not detected by standard genotyping methods. Each of these mutations was present in 5 to 20% of the 20 genomes analyzed; 15% of the genomes in this sample contained linked PI mutations, none of which were present in the standard genotype. In another patient sample, 33% of genomes contained five linked NNRTI resistance mutations, none of which were detected by standard genotype analysis. These findings illustrate the inadequacy of the standard genotype for detecting low-frequency drug resistance mutations. In addition to having greater sensitivity, single-genome sequencing identifies linked mutations that confer high-level drug resistance. Such linkage cannot be detected by standard genotype analysis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15635002      PMCID: PMC540111          DOI: 10.1128/JCM.43.1.406-413.2005

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  47 in total

1.  Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

Authors:  J Durant; P Clevenbergh; P Halfon; P Delgiudice; S Porsin; P Simonet; N Montagne; C A Boucher; J M Schapiro; P Dellamonica
Journal:  Lancet       Date:  1999-06-26       Impact factor: 79.321

2.  A strategy for cloning infectious molecular clones of retroviruses from serum or plasma.

Authors:  L Holterman; R Dubbes; J Mullins; J Haaijman; J Heeney
Journal:  J Virol Methods       Date:  2000-01       Impact factor: 2.014

3.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.

Authors:  H F Günthard; J K Wong; C C Ignacio; D V Havlir; D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

4.  Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group.

Authors:  L M Demeter; R D'Aquila; O Weislow; E Lorenzo; A Erice; J Fitzgibbon; R Shafer; D Richman; T M Howard; Y Zhao; E Fisher; D Huang; D Mayers; S Sylvester; M Arens; K Sannerud; S Rasheed; V Johnson; D Kuritzkes; P Reichelderfer; A Japour
Journal:  J Virol Methods       Date:  1998-11       Impact factor: 2.014

5.  Fidelity of HIV-1 reverse transcriptase.

Authors:  B D Preston; B J Poiesz; L A Loeb
Journal:  Science       Date:  1988-11-25       Impact factor: 47.728

6.  Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Authors:  R Shankarappa; J B Margolick; S J Gange; A G Rodrigo; D Upchurch; H Farzadegan; P Gupta; C R Rinaldo; G H Learn; X He; X L Huang; J I Mullins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions.

Authors:  Karin J Metzner; Sebastian Bonhoeffer; Marek Fischer; Rose Karanicolas; Kristina Allers; Beda Joos; Rainer Weber; Bernard Hirschel; Leondios G Kostrikis; Huldrych F Günthard
Journal:  J Infect Dis       Date:  2003-11-03       Impact factor: 5.226

8.  Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.

Authors:  Charlotte Charpentier; Dominic E Dwyer; Fabrizio Mammano; Denise Lecossier; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

Authors:  Elias K Halvas; Ann Wiegand; Valerie F Boltz; Mary Kearney; Dwight Nissley; Michael Wantman; Scott M Hammer; Sarah Palmer; Florin Vaida; John M Coffin; John W Mellors
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

10.  The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.

Authors:  V DeGruttola; L Dix; R D'Aquila; D Holder; A Phillips; M Ait-Khaled; J Baxter; P Clevenbergh; S Hammer; R Harrigan; D Katzenstein; R Lanier; M Miller; M Para; S Yerly; A Zolopa; J Murray; A Patick; V Miller; S Castillo; L Pedneault; J Mellors
Journal:  Antivir Ther       Date:  2000-03
View more
  296 in total

1.  Comparison of standard PCR/cloning to single genome sequencing for analysis of HIV-1 populations.

Authors:  Michael R Jordan; Mary Kearney; Sarah Palmer; Wei Shao; Frank Maldarelli; Eoin P Coakley; Colombe Chappey; Christine Wanke; John M Coffin
Journal:  J Virol Methods       Date:  2010-05-06       Impact factor: 2.014

2.  HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.

Authors:  Helene Mens; Mary Kearney; Ann Wiegand; Wei Shao; Kristian Schønning; Jan Gerstoft; Niels Obel; Frank Maldarelli; John W Mellors; Thomas Benfield; John M Coffin
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

3.  Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.

Authors:  Anu Osinusi; Anita Kohli; Miriam M Marti; Amy Nelson; Xiaozhen Zhang; Eric G Meissner; Rachel Silk; Kerry Townsend; Phillip S Pang; G Mani Subramanian; John G McHutchison; Anthony S Fauci; Henry Masur; Shyam Kottilil
Journal:  Ann Intern Med       Date:  2014-11-04       Impact factor: 25.391

4.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

5.  Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.

Authors:  Qing-Mao Geng; Han-Ping Li; Zuo-Yi Bao; Yong-Jian Liu; Dao-Min Zhuang; Lin Li; Si-Yang Liu; Jing-Yun Li
Journal:  Virol Sin       Date:  2010-10-08       Impact factor: 4.327

6.  Patterns of Human Immunodeficiency Virus type 1 recombination ex vivo provide evidence for coadaptation of distant sites, resulting in purifying selection for intersubtype recombinants during replication.

Authors:  Andrea Galli; Mary Kearney; Olga A Nikolaitchik; Sloane Yu; Mario P S Chin; Frank Maldarelli; John M Coffin; Vinay K Pathak; Wei-Shau Hu
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

7.  Rapid deep sequencing of patient-derived HIV with ion semiconductor technology.

Authors:  Max W Chang; Glenn Oliveira; Jinyun Yuan; Jason F Okulicz; Samuel Levy; Bruce E Torbett
Journal:  J Virol Methods       Date:  2013-02-04       Impact factor: 2.014

8.  Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.

Authors:  Mariacarmela Solmone; Donatella Vincenti; Mattia Carlo Felice Prosperi; Alessandro Bruselles; Giuseppe Ippolito; Maria Rosaria Capobianchi
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

9.  Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines.

Authors:  Ivo N SahBandar; Genesis Samonte; Elizabeth Telan; Nalyn Siripong; Mahdi Belcaid; David Schanzenbach; Susan Leano; Haorile Chagan-Yasutan; Toshio Hattori; Cecilia M Shikuma; Lishomwa C Ndhlovu
Journal:  AIDS Res Hum Retroviruses       Date:  2017-07-05       Impact factor: 2.205

10.  A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

Authors:  Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; Julie M Decker; Brandon F Keele; Jesus F Salazar-Gonzalez; Truman Grayson; David T McPherson; Li-Hua Ping; Jeffrey A Anderson; Ronald Swanstrom; Carolyn Williamson; George M Shaw; Beatrice H Hahn
Journal:  Virology       Date:  2009-12-08       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.